Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1996-10-18
|
| pubmed:abstractText |
Increased visceral adipose tissue is thought to contribute to impaired glucose tolerance. We studied 10 men with non-insulin dependent diabetes (NIDDM) before and after a 12-week intervention study using dexfenfluramine. Subjects had a mean body mass index (BMI) of 26.4 +/- 1.7 kg/m2 and had an abdominal distribution of body fatness (waist-to hip ratio > 0.9). Anthropometric indices, biochemistry, macronutrient intake from 7-day food records as well as a euglycaemic glucose clamp and magnetic resonance imaging (MRI) were performed at week 0 and week 12. Abdominal adipose tissue area measured by MRI was reduced from 854 +/- 270 cm2 to 666 +/- 231 cm2 (p = 0.003) due mainly to a selective 32% reduction in visceral fat area from 484 +/- 230 cm2 to 333 +/- 72 cm2 (p = 0.002). Insulin sensitivity improved from 0.29 +/- 0.13 [min-1 (mU/L)] to 0.54 +/- 0.21 [min-1 (mU/L)] (p = 0.01) and C-peptide levels reduced from 0.77 +/- 0.24 mumol/L to 0.58 +/- 0.15 mumol/L (p = 0.002). The reductions in fasting glucose and glycated haemoglobin failed to achieve significance. Fasting total cholesterol and triglyceride levels significantly reduced (p = < 0.001 and p = 0.021 respectively). There was a reduction in total energy intake (p = 0.005) due to a significant reduction in calories obtained from fat (p < 0.001). Thus dexfenfluramine was shown to be a useful adjunct therapy for the reduction of visceral fat in abdominally-obese men with NIDDM with an associated improvement in insulin sensitivity.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Appetite Depressants,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol,
http://linkedlifedata.com/resource/pubmed/chemical/Fenfluramine,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1071-7323
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
4
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1-7
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:8787932-Adipose Tissue,
pubmed-meshheading:8787932-Adult,
pubmed-meshheading:8787932-Appetite Depressants,
pubmed-meshheading:8787932-Body Composition,
pubmed-meshheading:8787932-Body Constitution,
pubmed-meshheading:8787932-Body Mass Index,
pubmed-meshheading:8787932-Cholesterol,
pubmed-meshheading:8787932-Diabetes Mellitus, Type 2,
pubmed-meshheading:8787932-Diet,
pubmed-meshheading:8787932-Energy Intake,
pubmed-meshheading:8787932-Fenfluramine,
pubmed-meshheading:8787932-Humans,
pubmed-meshheading:8787932-Insulin,
pubmed-meshheading:8787932-Magnetic Resonance Imaging,
pubmed-meshheading:8787932-Male,
pubmed-meshheading:8787932-Middle Aged,
pubmed-meshheading:8787932-Obesity,
pubmed-meshheading:8787932-Triglycerides
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM.
|
| pubmed:affiliation |
Sheikh Rashid Diabetes Unit, Radcliffe Infirmary Oxford, UK.
|
| pubmed:publicationType |
Journal Article
|